Clinical trial • Phase I • Oncology
CC-1 (PSMAxCD3 bispecific antibody) for Recurrent prostate cancer
Phase I trial of CC-1 (PSMAxCD3 bispecific antibody) for Recurrent prostate cancer. None/Not specified-controlled. 56 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Recurrent prostate cancer
- Trial Stage
- Phase I
- Drug Modality
- Bispecific antibody
Key dates
- Initial CTIS Submission Date
- 12-02-2024
- First CTIS Authorization Date
- 05-03-2024
Trial design
None/Not specified-controlled Phase I trial across 1 site in Germany.
- Comparator
- None/Not specified
- Target Sample Size
- 56
Eligibility
Recruits 56 Vulnerable population not selected; no special consent or assent handling is described in the available documentation..
- Vulnerable Population
- Vulnerable population not selected; no special consent or assent handling is described in the available documentation.
Recruitment
- Planned Sample Size
- 56
- Recruitment Window Months
- 49
- Consent Approach
- Informed consent obtained from adult participants; no vulnerable populations selected; no details on assent, age-specific documents, or languages available in the provided records.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 56
Germany
- Earliest CTIS Part Ii Submission Date
- 01-02-2024
- Latest Decision Or Authorization Date
- 26-03-2025
- Processing Time Days
- 419
- Number Of Sites
- 1
- Number Of Participants
- 56
Sites
- Site Name
- Universitaetsklinikum Tuebingen AöR
- Department Name
- KKE Translationale Immunologie
- Contact Person Name
- Juliane Walz
- Contact Person Email
- kketi@med.uni-tuebingen.de
- Number Of Participants
- 56
Sponsor
Primary sponsor
- Full Name
- Universitaetsklinikum Tuebingen AöR
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Germany
Investigational products
- Investigational Product Name
- CC-1
- Active Substance
- CC-1 (PSMAxCD3 bispecific antibody)
- Modality
- Bispecific antibody
Related trials
Other published trials that may interest you.
- PEMBROLIZUMAB for Recurrent prostate cancer
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer